Anti-PVRIG antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-9714289-B2
Application number	US-201615277978-A
Country	US
Kind code	B2
Filing date	Sep 27, 2016
Priority date	Feb 19, 2015
Publication date	Jul 25, 2017
Grant date	Jul 25, 2017

Abstract

The present invention is directed to anti-PVRIG antibodies and methods of using same.

First claim

The invention claimed is:

1. A method of activating T-cells of a patient with cancer comprising administering an anti-PVRIG antibody to said patient, wherein said antibody comprises:
i) the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:1434 and
ii) the vlCDR1, vlCDR2, and vlCDR3 from SEQ ID NO:1453,

wherein a subset of said T-cells of said patient are activated.

2. A method according to claim 1 wherein said antibody comprises the heavy chain variable domain of SEQ ID NO:1434 and the light chain variable domain of SEQ ID NO:1453.

3. A method according to claim 2 wherein said antibody further comprises the CH1-hinge-CH2-CH3 region from IgG1, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations.

4. A method according to claim 2 wherein said antibody further comprises the CL region of human kappa 2 light chain.

5. A method according to claim 1 wherein said T-cells are cytotoxic T-cells (CTLs).

6. A method according to claim 1 wherein said T-cells are selected from the group consisting of CD4 + T-cells and CD8 + T-cells.

7. A method according to claim 1 wherein said activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

8. A method of activating T-cells of a patient with cancer comprising administering an anti-PVRIG antibody to said patient, wherein said antibody comprises:
i) the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:1447 and
ii) the vlCDR1, vlCDR2, and vlCDR3 from SEQ ID NO:1462,

wherein a subset of said T-cells of said patient are activated.

9. A method according to claim 8 wherein said antibody comprises the heavy chain variable domain of SEQ ID NO:1447 and the light chain variable domain of SEQ ID NO:1462.

10. A method according to claim 9 wherein said antibody further comprises the CH1-hinge-CH2-CH3 region from IgG1, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations.

11. A method according to claim 9 wherein said antibody further comprises the CL region of human kappa 2 light chain.

12. A method according to claim 8 wherein said T-cells are cytotoxic T-cells (CTLs).

13. A method according to claim 8 wherein said T-cells are selected from the group consisting of CD4 + T-cells and CD8 + T-cells.

14. A method according to claim 8 wherein said activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

15. A method of activating T-cells of a patient with cancer comprising administering an anti-PVRIG antibody to said patient, wherein said antibody comprises:
a) a heavy chain variable domain comprising:
i) a vhCDR1 comprising SEQ ID NO:885;
ii) a vhCDR2 comprising SEQ ID NO:886;
iii) a vhCDR3 comprising SEQ ID NO:887; and

b) a light chain variable domain comprising:
i) a vlCDR1 comprising SEQ ID NO:889;
ii) a vlCDR2 comprising SEQ ID NO:890;
iii) a vlCDR3 comprising SEQ ID NO:891,

wherein a subset of said T-cells of said patient are activated.

16. A method according to claim 15 wherein said antibody further comprises the CH1-hinge-CH2-CH3 region from IgG1, IgG2, IgG3, or IgG4, wherein said hinge region optionally comprises mutations.

17. A method according to claim 15 wherein said antibody further comprises the CL region of human kappa 2 light chain.

18. A method according to claim 15 wherein said T-cells are cytotoxic T-cells (CTLs).

19. A method according to claim 15 wherein said T-cells are selected from the group consisting of CD4 + T-cells and CD8 + T-cells.

20. A method according to claim 15 wherein said activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.

Assignees

• Compugen Ltd

Inventors

• White Mark
• Kumar Sandeep
• Chan Christopher
• Liang Spencer
• Stapleton Lance
• Drake Andrew W
• Gozlan Yosi
• Vaknin Ilan
• Sameah-Greenwald Shirley
• Dassa Liat
• Tiran Zohar
• Cojocaru Gad S
• Presta Leonard
• Theolis Richard

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title